Related Experiment Videos
Activity of meropenem and other antimicrobial agents against uncommon gram-negative organisms
Abstract:
The in-vitro activity of meropenem and other antimicrobial agents was tested by agar dilution against 113 uncommon Gram-negative pathogens. Both meropenem and ceftriaxone showed the most activity against the test isolates. The potency of meropenem was greater than imipenem against Pasteurella multocida, Eikenella corrodens, Haemophilus parainfluenzae, Moraxella spp., Kingella spp., and Actinobacillus actinomycetemcomitans. Further work is necessary to assess the in-vivo activity of meropenem against these Gram-negative isolates.
Insights
Meropenem demonstrates potent in-vitro activity against uncommon Gram-negative pathogens, outperforming imipenem in several species. Further in-vivo studies are needed to confirm its efficacy.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Uncommon Gram-negative pathogens pose challenges in clinical settings.
- Evaluating novel antimicrobial agents is crucial for combating resistant infections.
Purpose of the Study:
- To assess the in-vitro antimicrobial activity of meropenem and other agents against 113 uncommon Gram-negative pathogens.
- To compare the potency of meropenem with other antimicrobials, including imipenem.
Main Methods:
- Agar dilution method was employed for in-vitro susceptibility testing.
- The study included 113 isolates of uncommon Gram-negative pathogens.
Main Results:
- Meropenem and ceftriaxone exhibited the highest activity against the tested Gram-negative isolates.
- Meropenem showed greater potency than imipenem against specific pathogens: Pasteurella multocida, Eikenella corrodens, Haemophilus parainfluenzae, Moraxella spp., Kingella spp., and Actinobacillus actinomycetemcomitans.
Conclusions:
- Meropenem is a promising antimicrobial agent with significant in-vitro activity against a range of uncommon Gram-negative bacteria.
- Further in-vivo investigations are warranted to establish the clinical efficacy of meropenem for infections caused by these pathogens.